SeeTreat has been working with seven large US networks on early access and research programs in the USA. We are pleased that these groups will now be able to use ART.1-US clinically as well as for their research programs.

Professor Jeff Siebers of the University of Virginia says “Having piloted a research version of SeeTreat’s ART.1 software, our team has seen how automated adaptive decision support can help clinical teams efficiently evaluate whether anatomic changes during radiotherapy are dosimetrically consequential throughout a patient’s treatment course. This type of structured, dosimetry-based assessment can support evidence-based replanning decisions. With ART.1-US advancing to an FDA-cleared product for clinical use, it brings the potential to support broader implementation of personalized adaptive radiotherapy.”

SeeTreat CEO and Founder, Dr Trang Nguyen said “This is a landmark moment for the SeeTreat team. FDA clearance of ART.1-US brings our intelligent adaptive radiotherapy solution to the single largest radiotherapy market in the world, extending our reach beyond the UK, Europe, and Australia. As we pursue our mission of equitable access to highly personalised radiotherapy, this milestone marks a new chapter in scaling ART.1 globally. We look forward to partnering with US clinics to unlock the full potential of offline adaptive radiotherapy for the benefits of US cancer patients.”